Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 8/20 | 0.40 |
| ▸ | SCN2B | O60939 | 6/20 | 0.40 |
| ▸ | SCN1B | Q07699 | 6/20 | 0.40 |
| ▸ | SCN1A | P35498 | 3/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | MMP13 | P45452 | 2/20 | 0.38 |
| ▸ | HTR7 | P34969 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11024311 | 0.92 | MMP2 (0.38) | SCN9ASCN2BSCN1BSCN1AMMP2 | |
| SCHEMBL11940904 | 0.87 | SCN9A (0.40) | SCN9ASCN2BSCN1BSCN1ASCN5A | |
| SCHEMBL11025741 | 0.86 | POLB (0.38) | MMP2MMP13MAPTTP53 | |
| SCHEMBL11027123 | 0.86 | MAPT (0.36) | MMP2MMP13CA2CA7CA9 | |
| SCHEMBL11027058 | 0.83 | MAPT (0.46) | MAPTTP53 | |
| SCHEMBL11023804 | 0.81 | MMP2 (0.39) | SCN9ASCN2BSCN1BSCN1ASCN5A | |
| SCHEMBL11027051 | 0.80 | CHEK1 (0.40) | IP6K1MAPTGSK3B | |
| SCHEMBL11940885 | 0.78 | SCN9A (0.48) | SCN9ASCN2BSCN1BSCN1ASCN5A | |
| SCHEMBL11940903 | 0.78 | SCN9A (0.38) | SCN9ASCN2BSCN1BSCN1ASCN5A | |
| SCHEMBL11940901 | 0.78 | SCN9A (0.39) | SCN9ASCN2BSCN1BSCN1ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809369-B2 | Tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809369-B2 | Tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-08-19 | — | — | US | disclosed |
| WO-2012101068-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| US-20120190677-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | US | disclosed |
| US-20120190677-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190677-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | RAB1A, RABL3, RAB7A | SCN9A 1420/4885SCN2B 741/4885SCN1B 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.